Chronic kidney disease - Effects on the cardiovascular system

被引:1173
作者
Schiffrin, Ernesto L.
Lipman, Mark L.
Mann, Johannes F. E.
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada
[2] Univ Munich, Schwabing Gen Hosp, Dept Hypertens & Nephrol, Munich, Germany
关键词
atherosclerosis; hypertension; kidney; vasculature;
D O I
10.1161/CIRCULATIONAHA.106.678342
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Accelerated cardiovascular disease is a frequent complication of renal disease. Chronic kidney disease promotes hypertension and dyslipidemia, which in turn can contribute to the progression of renal failure. Furthermore, diabetic nephropathy is the leading cause of renal failure in developed countries. Together, hypertension, dyslipidemia, and diabetes are major risk factors for the development of endothelial dysfunction and progression of atherosclerosis. Inflammatory mediators are often elevated and the renin-angiotensin system is frequently activated in chronic kidney disease, which likely contributes through enhanced production of reactive oxygen species to the accelerated atherosclerosis observed in chronic kidney disease. Promoters of calcification are increased and inhibitors of calcification are reduced, which favors metastatic vascular calcification, an important participant in vascular injury associated with end-stage renal disease. Accelerated atherosclerosis will then lead to increased prevalence of coronary artery disease, heart failure, stroke, and peripheral arterial disease. Consequently, subjects with chronic renal failure are exposed to increased morbidity and mortality as a result of cardiovascular events. Prevention and treatment of cardiovascular disease are major considerations in the management of individuals with chronic kidney disease.
引用
收藏
页码:85 / 97
页数:13
相关论文
共 122 条
[71]   The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis [J].
Nitta, K ;
Akiba, T ;
Uchida, K ;
Kawashima, A ;
Yumura, W ;
Kabaya, T ;
Nihei, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (02) :303-309
[72]   Stiffness of capacitive and conduit arteries prognostic significance for end-stage renal disease patients [J].
Pannier, B ;
Guèrin, AP ;
Marchais, SJ ;
Safar, ME ;
London, GM .
HYPERTENSION, 2005, 45 (04) :592-596
[73]  
Parfrey PS, 1999, J AM SOC NEPHROL, V10, P1606
[74]   Leptin enhances the calcification of vascular cells - Artery wall as a target of leptin [J].
Parhami, F ;
Tintut, Y ;
Ballard, A ;
Fogelman, AM ;
Demer, LL .
CIRCULATION RESEARCH, 2001, 88 (09) :954-960
[75]   Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide [J].
Passauer, J ;
Pistrosch, F ;
Büssemaker, E ;
Lässig, G ;
Herbrig, K ;
Gross, P .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04) :959-965
[76]   A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients [J].
Pecoits, R ;
Stenvinkel, P ;
Marchlewska, A ;
Heimburger, O ;
Bárány, P ;
Hoff, CM ;
Holmes, CJ ;
Suliman, M ;
Lindholm, B ;
Schalling, M ;
Nordfors, L .
KIDNEY INTERNATIONAL, 2003, 63 :S172-S176
[77]   Associations between circulating inflammatory markers and residual renal function in CRF patients [J].
Pecoits, R ;
Heimbürger, O ;
Bárány, P ;
Suliman, M ;
Fehrman-Ekholm, I ;
Lindholm, B ;
Stenvinkel, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (06) :1212-1218
[78]   Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study [J].
Perkins, BA ;
Nelson, RG ;
Ostrander, BEP ;
Blouch, KL ;
Krolewski, AS ;
Myers, BD ;
Warram, JH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1404-1412
[79]   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both [J].
Pfeffer, MA ;
McMurray, JJV ;
Velazquez, EJ ;
Rouleau, JL ;
Kober, L ;
Maggioni, AP ;
Solomon, SD ;
Swedberg, K ;
Van de Werf, F ;
White, H ;
Leimberger, JD ;
Henis, M ;
Edwards, S ;
Zelenkofske, S ;
Sellers, MA ;
Califf, RM ;
Aylward, P ;
Armstrong, P ;
Barvik, S ;
Belenkov, Y ;
Dalby, A ;
Diaz, R ;
Drexler, H ;
Ertl, G ;
Francis, G ;
Hampton, J ;
Harsanyi, A ;
Kvasnicka, J ;
Mareev, V ;
Marin-Neto, J ;
Murin, J ;
Myers, M ;
Nordlander, R ;
Opolski, G ;
Soler-Soler, J ;
Spac, J ;
Stefenelli, T ;
Sugrue, D ;
Van Gilst, W ;
Varshavsky, S ;
Weaver, D ;
Zannad, F ;
Aguilar, D ;
Alvarez, A ;
Al-Taweel, M ;
Anavekar, N ;
Finn, P ;
Lopez-Jimenez, F ;
Mercier, R ;
Lewis, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1893-1906
[80]   Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix γ-carboxyglutamic acid protein in the serum of etidronate-treated rats [J].
Price, PA ;
Thomas, GR ;
Pardini, AW ;
Figueira, WF ;
Caputo, JM ;
Williamson, MK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (06) :3926-3934